Lyn

Atari’s Spook-tacular Stealth-Strategy Roguelite Haunted House is Now Available on PC and Consoles

Retrieved on: 
Thursday, October 12, 2023
Atari 2600, Egg as food, Tooniverse, Precocious, House, Lyn, Chills, Human, Friends, Video game, Nightclub, Haunted house

In a nod to the original, Haunted House rewards stealth gameplay and problem-solving while de-emphasizing combat.

Key Points: 
  • In a nod to the original, Haunted House rewards stealth gameplay and problem-solving while de-emphasizing combat.
  • A modern touch is the addition of a roguelite element, as rooms within the mansion shift and change with every run.
  • Watch the Haunted House launch trailer:
    In Haunted House, players take control of Lyn Graves, the precocious niece of legendary treasure hunter Zachary Graves.
  • Key Features of Haunted House Include:
    All-Ages Thrill Ride: The whimsical, cartoonish art style only thinly veils the chills and thrills in Haunted House!

Chills and Stealthy Thrills Galore in Haunted House, the Latest Reimagining from Atari — Coming to PC and Consoles Later This Year

Retrieved on: 
Monday, June 26, 2023
Human, PlayStation 4, Friends, BIG, Chills, Lyn, Microsoft Windows, Atari, Xbox One, PC, Brazilian, Nintendo Switch, Egg as food, Tooniverse, Precocious, House, PlayStation, Paulo, Atari 2600, Video game, Nightclub, Haunted house, Haunted

Coming to PC and consoles later this year, Haunted House pays homage to the original survival-horror adventure by seamlessly adopting dynamic roguelite elements while incorporating stealth-based gameplay and haunting boss battles.

Key Points: 
  • Coming to PC and consoles later this year, Haunted House pays homage to the original survival-horror adventure by seamlessly adopting dynamic roguelite elements while incorporating stealth-based gameplay and haunting boss battles.
  • The Brazil-based developers behind Haunted House, Orbit Studio, will be featured live and on-stage in the show’s programming.
  • In Haunted House, players take control of Lyn Graves, the precocious niece of legendary treasure hunter Zachary Graves.
  • All-Ages Thrill Ride: The whimsical, cartoonish art style only thinly veils the chills and thrills in Haunted House!

Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2

Retrieved on: 
Tuesday, April 18, 2023
TKI, ACC, AACR, PDGFR, Hepatocellular carcinoma, Progression-free survival, ESMO, American Society of Clinical Oncology, Food and Drug Administration, NDA, Cancer, American Association for Cancer Research, Toxicity, Adenoid cystic carcinoma, Oncology, FLT4, European Society for Medical Oncology, Liver cancer, ASCO, Congress, Patient, Sorafenib, VEGFR, Toxic encephalopathy, Neoplasm, Apatinib, PD-1, FDA, Therapy, FLT1, Society, HCC, Food, Pharmaceutical industry, Lyn

The results of the analysis were shared today in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.

Key Points: 
  • The results of the analysis were shared today in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.
  • For the biochemical analysis, the activity of rivoceranib and 10 U.S. Food and Drug Administration (FDA)-approved TKIs with known activity against VEGFR-2 were compared against a panel of 270 kinases.
  • Substantial differences in overall residual kinase activity were observed across the panel of 270 kinases among the 11 inhibitors.
  • Rivoceranib is the most selective inhibitor of VEGFR-2 kinase activity among the tested inhibitors.

MOTORCAR CAVALCADE MIAMI ANNOUNCES PREVIEW OF STAR CARS AND VIP PANEL OF JUDGES FOR THIS YEAR'S EPIC EXTRAVAGANZA

Retrieved on: 
Monday, November 21, 2022
Dashboard, Beauty, Car, Rolls-Royce Phantom II, Concours, Ferrari, Selection Committee, Collection, Woman, Bugatti Type 57, Pagani, American Cancer Society, Ferrari 250, Motorsports Hall of Fame, Lyn St. James, Motorsports Hall of Fame of America, Bugatti, Apollo Intensa Emozione, Convertible, Hennessey, Docent, Multimedia, ACS, Female, Lyn, Bubble, Hennessey Performance Engineering, Ferris Bueller's Day Off, Citroën DS, VIP, Fireside chats, General Motors, Miami Heat, Nightclub, Entertainment, Sound

MIAMI, Nov. 21, 2022 /PRNewswire/ -- Motorcar Cavalcade, the must-attend event for every automobile enthusiast from connoisseur to the car-curious, announces its preliminary lineup of celebrity judges and a peek into the vibrant collection of the automobiles, from iconic vintage classics to modern exotics. The event, now in its second year, will be held on the lush fairway of the JW Marriott Turnberry Resort's golf course on January 15th in Aventura, Miami.

Key Points: 
  • The 2023 event judges are VIP celebrities, sports stars and some of the world's leading automotive figures including Motorsports Hall of Fame racing legends Lyn St. James and Tommy Kendall.
  • "This year's Motorcar Cavalcade will be nothing short of incredible," says Jason Wenig, Motorcar Cavalcade Co-Executive Director.
  • Motorcar Cavalcade has partnered with the American Cancer Society, and will hold a digital auction with 100% of the proceeds donated to the ACS.
  • Over 100 classic and modern cars playfully compete in 16 atypical classes including Dashboards, Doors, Tails, Sound, and Engine to secure their prized trophy.

Tracy J. Edmonds Joins Lyn Health Board of Advisors

Retrieved on: 
Thursday, February 3, 2022
Fitness & Nutrition, Health, CEO, Leadership, Culture, Organization, Empathy, DEI, LLC, Woman, Instagram, Facebook, Strategic planning, Amazon, Love, Journal, HR, Health, Central Waqf Council, Organizational studies, Multimedia, LinkedIn, Tracy, Emphasis (typography), Anthem Inc. (album), Management, Lyn, Gallup, Anthem

Lyn Health, a pioneering healthcare start-up focused on people with multiple chronic conditions, today announced the addition of Tracy J. Edmonds, former Chief Diversity Officer of Anthem, Inc., to its Board of Advisors.

Key Points: 
  • Lyn Health, a pioneering healthcare start-up focused on people with multiple chronic conditions, today announced the addition of Tracy J. Edmonds, former Chief Diversity Officer of Anthem, Inc., to its Board of Advisors.
  • Lyn Health embraces diversity, equity and inclusion as foundational values for the future success of this company, said Rick Abbott, Founder and CEO of Lyn Health.
  • Companies that embrace DEI as a strategic imperative have consistently shown both improved employee experience and superior business results, said Edmonds.
  • Tracy J. Edmonds is the owner of TJE Coaching & Consulting, LLC, where she serves as an executive coach and diversity, equity, and inclusion (DEI) consultant.

Naomi Allen Joins Lyn Health Board of Advisors

Retrieved on: 
Monday, December 20, 2021
Mental Health, Teens, Children, Practice Management, Family, Managed Care, Health, Consumer, General Health, Health, Courage, Central Waqf Council, Empathy, IPO, Business, Industry, University of North Carolina at Chapel Hill, Stanford Graduate School of Business, Acquisition, Entrepreneurship, Castlight Health, CEO, Naomi, Love, Multimedia, MBA, Silicon, Medicine, Management, Lyn, Brightline

Lyn Health, a pioneering healthcare start-up focused on people with multiple chronic conditions, announced today the addition of Naomi Allen, CEO and Co-Founder of Brightline, to its Board of Advisors.

Key Points: 
  • Lyn Health, a pioneering healthcare start-up focused on people with multiple chronic conditions, announced today the addition of Naomi Allen, CEO and Co-Founder of Brightline, to its Board of Advisors.
  • Prior to starting Brightline, she was the Chief Growth Officer for Livongo and a founding team member of Castlight Health.
  • Naomi is one of the preeminent entrepreneurs in all of healthcare, having led multiple successful endeavors that have transformed the industry, said Rick Abbott, Founder and CEO of Lyn Health.
  • Naomi Allen is the co-founder and CEO of Brightline, the leader in technology-enabled pediatric behavioral health care.

Healthcare Management Administrators (HMA) Partners with Lyn Health to Provide Enhanced Care Support for Polychronic Members

Retrieved on: 
Wednesday, December 15, 2021
Managed Care, General Health, Health, Other Health, LinkedIn, Solution, Empathy, Creativity, Industry, HMA, CEO, Goal, Patient, Love, Multimedia, Partnership, Health, Health insurance, Medicine, Lyn

Healthcare Management Administrators (HMA), a pioneer in self-funded health benefit programs and one of the nations largest third-party administrators, announced today a new partnership with Lyn Health to make Lyns industry-leading clinical care model available for its members with multiple chronic conditions.

Key Points: 
  • Healthcare Management Administrators (HMA), a pioneer in self-funded health benefit programs and one of the nations largest third-party administrators, announced today a new partnership with Lyn Health to make Lyns industry-leading clinical care model available for its members with multiple chronic conditions.
  • Leveraging virtual capabilities and in-person resources, Lyn improves quality of care and lowers cost for the polychronic population.
  • Partnering with Lyn further expands upon our core care management products and provides even greater value to our customers.
  • The partnership between Lyn and HMA establishes a new industry standard for member care, said Rick Abbott, Founder and CEO of Lyn.

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
Monday, September 13, 2021

This indicates that the development and review of amdizalisib for relapsed or refractory FL may be expedited, to address patients' unmet needs more quickly.

Key Points: 
  • This indicates that the development and review of amdizalisib for relapsed or refractory FL may be expedited, to address patients' unmet needs more quickly.
  • In April 2021, HUTCHMED initiated a Phase II registration study in China for amdizalisib in approximately 100 patients with relapsed or refractory FL and approximately 80 patients with marginal zone lymphoma (MZL).
  • Amdizalisib is also being evaluated in an ongoing Phase I/Ib study in the U.S. and Europe in patients with relapsed or refractory NHL ( NCT03786926 ).
  • Patients with relapsed or refractory FL do not have curative treatment options and have a high unmet need for optimal therapeutic options.

Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals

Retrieved on: 
Tuesday, September 7, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Diabetes, Clinical Trials

The acquisition broadens Novaremeds existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the Companys focus area.

Key Points: 
  • The acquisition broadens Novaremeds existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the Companys focus area.
  • Moreover, it enables Novaremed to target a wider spectrum of neuropathic pain indications, potentially also addressing broader applications by including prevention in addition to the treatment of pain.
  • Integrating Metys technologies and pipeline into Novaremed represents the best way forward towards accomplishing these goals.
  • Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully-owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland).